Amgen Does Not Expect Big Enbrel Price Impact From US Humira Biosimilar Launches

Q3 Revenue Down 1% But Beat Analyst Consensus

 
• By Mandy Jackson

Amgen will be first to launch a Humira biosimilar in the US with its Amgevita, but it and other adalimumab copies may add pressure to the company’s already declining top-seller Enbrel.

Sign from Amgen building in Switzerland
Amgen's $6.65bn in Q3 revenue beat consensus expectations of $6.57bn • Source: Shutterstock

More from Drug Pricing

More from Scrip